~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~
Read more:
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
Mechelen, Belgium; 11 November 2022, 13.15 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders.
Follow this link:
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Read the original post:
Avicanna Announces Closing of Non-Brokered Private Placement
- The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy-
WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/be19ab99-a0c8-4850-a0a4-1592fdc18600
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Biomea’s management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.
Read this article:
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022.
See the original post:
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis Robust two-year X-ray results of medial joint space width (mJSW) and significant pain response in patients with earlier disease highlight the potential of lorecivivint to be a first-in-class, structure-modifying drug for the treatment of knee osteoarthritis
Excerpt from:
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated ?9?2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors
Here is the original post:
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting